孕期接种新冠疫苗的围产期死亡与早产风险:CDC妊娠登记队列研究
本研究基于CDC新冠疫苗妊娠登记(C19VPR)观察性队列,纳入2020年12月至2021年6月接种至少1剂新冠疫苗的孕妇,匹配2019年全国生命统计系统(NVSS)数据,采用风险胎儿法估算围产期死亡和早产风险。结果显示接种组围产期死亡累积风险为4.8/1000活产,早产为6.6%,均低于匹配的2019年NVSS估计(8.1/1000和12.1%),调整后风险比分别为0.62和0.55,未见风险升高。
要点
- 孕期接种新冠疫苗未增加围产期死亡风险(aHR 0.62,95%CI 0.46-0.83)。
- 孕期接种新冠疫苗未增加早产风险(aHR 0.55,95%CI 0.51-0.58)。
- 不同疫苗厂商间围产期死亡和早产风险无差异。
核心结论
- 孕期接种新冠疫苗未发现围产期死亡或早产风险升高的证据。
研究设计与样本
- CDC新冠疫苗妊娠登记(C19VPR)为观察性队列,纳入2020年12月15日至2021年6月21日接种至少1剂新冠疫苗的孕妇,接种时间在末次月经前30天至妊娠期间。
- 通过电话访谈收集数据,按种族、民族和年龄组匹配2019年美国国家生命统计系统(NVSS)数据。
- 采用风险胎儿法估算单胎妊娠(孕周≥6周)的围产期死亡和早产风险,并用Cox回归计算调整风险比(aHR)。
主要发现
- C19VPR妊娠围产期死亡累积风险为4.8/1000活产,NVSS为8.1/1000活产。
- C19VPR妊娠早产累积风险为6.6%,NVSS为12.1%。
- 调整种族、民族、年龄和孕前BMI后,C19VPR妊娠围产期死亡风险低于2019年NVSS(aHR 0.62,95%CI 0.46-0.83)。
- 调整后早产风险亦低于2019年NVSS(aHR 0.55,95%CI 0.51-0.58)。
- C19VPR队列内围产期死亡和早产风险在不同疫苗厂商间无差异。
临床怎么用
- 可为孕期女性接种新冠疫苗的安全性咨询提供证据,支持现有临床推荐。
- 不同新冠疫苗厂商的围产期风险未见差异,选择疫苗时无需考虑此因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COVID-19 vaccine clinical trials excluded pregnant women; additional data on safety of COVID-19 vaccines in pregnancy can strengthen clinical recommendations. OBJECTIVE: To assess risk of perinatal death (stillbirth and neonatal death), and preterm birth among women receiving COVID-19 vaccines just prior to or during pregnancy. METHODS: The Centers for Disease Control and Prevention's COVID-19 Vaccine Pregnancy Registry (C19VPR) is an observational cohort of women receiving ≥1 COVID-19 vaccine between December 15, 2020, and June 21, 2021, up to 30 days before their last menstrual period or during pregnancy. Data were collected through interviewer-administered phone surveys. We matched C19VPR pregnancies to 2019 US National Vital Statistics System (NVSS) data based on race, ethnicity, and age group. We estimated week-specific and cumulative risk of perinatal death and preterm birth using a fetuses-at-risk approach among singleton pregnancies ending ≥6 weeks' gestation. For C19VPR participants, pregnancies entered the risk pool at gestational age of vaccination. We compared C19VPR estimates to NVSS using Cox regression to calculate hazard ratios and 95% confidence intervals adjusted for race, ethnicity, age, and pre-pregnancy body mass index. Among C19VPR pregnancies, we used Cox regression to assess difference in risk by vaccine manufacturer. RESULTS: Cumulative risk of perinatal death among C19VPR pregnancies and NVSS were 4.8 and 8.1 per 1000 births, respectively. Cumulative risk of preterm births among C19VPR pregnancies and NVSS were 6.6% and 12.1%, respectively. Adjusted hazard ratios (aHR) suggested lower cumulative risk of perinatal death and preterm birth among C19VPR pregnancies (vaccinated) compared with 2019 NVSS (pre-pandemic estimate) (aHR 0.62 95%CI 0.46, 0.83; aHR 0.55 95%CI 0.51, 0.58, respectively). Within the C19VPR cohort, risks of perinatal death and preterm birth did not differ by vaccine manufacturer. CONCLUSION: We found no evidence of increased risk of perinatal death or preterm birth after COVID-19 vaccination in pregnancy.
引用
- Madni SA, Olson CK, Zauche LH, et al. Risk of perinatal death and preterm birth among an observational cohort of women vaccinated against SARS-CoV-2 in pregnancy: CDC COVID-19 vaccine pregnancy registry. Vaccine. 2026. PMID: 41833131. doi:10.1016/j.vaccine.2026.128461
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。